- Home
- ALVO vs SABR Comparison
ALVO vs SABR Comparison
Compare ALVO & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALVO | SABR |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Luxembourg | United States |
| Employees | 1460 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 842.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALVO | SABR |
|---|---|---|
| Price | $3.06 | $1.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.00 | $1.50 |
| AVG Volume (30 Days) | 638.7K | ★ 3.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 283.56 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $3,866,956,000.00 |
| Revenue This Year | $13.28 | $7.51 |
| Revenue Next Year | $18.63 | $3.46 |
| P/E Ratio | ★ $18.20 | $84.50 |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $2.94 | $0.81 |
| 52 Week High | $9.94 | $3.20 |
Technical Indicators
Market Signals| Indicator | ALVO | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 41.36 |
| Support Level | $2.99 | $1.51 |
| Resistance Level | $3.94 | $1.70 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 0.98 | 8.93 |
Price Performance
Historical ComparisonAbout ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.